Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats

Toxicology

Volumn 293, Issue 1-3, 2012, Pages 1-15

  Butenhoff, John L ^a   Chang, Shu Ching ^a   Olsen, Geary W ^a   Thomford, Peter J ^b  

^a 3M COMPANY   (United States)

^b 206 Carnegie Center   (United States)

Author keywords

Dietary; Oncogenicity; Perfluorooctanesulfonate; PFOS; Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLORIDE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; PERFLUOROOCTANESULFONATE POTASSIUM; PERFLUOROOCTANESULFONIC ACID; PHOSPHATE; POTASSIUM; PROTEIN; SODIUM; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; BILIRUBIN BLOOD LEVEL; BIOASSAY; BODY WEIGHT; CARCINOGENICITY; CELL PROLIFERATION; CELL VACUOLE; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOPLASM; DIETARY INTAKE; ENDOPLASMIC RETICULUM; EOSINOPHIL; ERYTHROCYTE COUNT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HISTOPATHOLOGY; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER HYPERTROPHY; MALE; MEAN CORPUSCULAR VOLUME; MORTALITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SODIUM BLOOD LEVEL; SURVIVAL TIME; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

ADENOMA, LIVER CELL; ALKANESULFONIC ACIDS; ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; HYPERTROPHY; LIVER; LIVER NEOPLASMS; MALE; ORGAN SPECIFICITY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; TOXICITY TESTS, CHRONIC; VACUOLES;

RATTUS;

EID: 84862785563     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.01.003     Document Type: Article

References (43)

1. Alexander B.H., Olsen G.W., Burris J.M., Mandel J.H., Mandel J.S. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 2003, 60:722-729.
2. Alexander B.H., Olsen G.W. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann. Epidemiol. 2007, 17:471-478.
3. Bailer A.J., Portier C.J. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 1988, 44:417-431.
4. Bijland S., Rensen P.C.N., Pieterman E.J., Maas A.C.E., van der Hoorn J.W., Van Erk M.J., Havekes L.M., van Dijk K.W., Chang S.-C., Ehresman D.J., Butenhoff J.L., Princen H.M.G. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-leiden CETP mice. Toxicol. Sci. 2011, 123:290-303.
5. Bjork J.A., Butenhoff J.L., Wallace K.B. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 2011, 288:8-17.
6. Chang, S.-C., Noker, P.E., Gorman, G.S., Gibson, S.J., Hart, J.A., Ehresman, D.J., Butenhoff, J.L., 2012. Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod. Toxicol., , in press. doi:10.1016/j.reprotox.2011.07.002.
7. Cui L., Zhou Q., Liao C., Fu J., Jiang G. Studies on the toxicological effects of PFOA and PFOS on rats using histological observation and chemical analysis. Arch. Environ. Contam. Toxicol. 2009, 56:338-349.
8. Dinse G.E., Lagakos S.W. Regression analysis of tumor prevalence data. J. Roy. Stat. Soc. C (Appl. Stat.) 1983, 32:236-248.
9. Dunnett C.W. New tables for multiple comparisons with a control. Biometrics 1964, 20:482-491.
10. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.C., Ehresman D.J., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology 2012, 293:16-29.
11. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.C., Ehresman D.J., Noker P.E., Butenhoff J.L. Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology 2012, 293:30-40.
12. Eriksen K.T., Sorensen M., McLaughlin J.K., Lipworth L., Tjonneland A., Overvad K., Raaschou-Nielsen O. Perfluorooctanoate and Perfluorooctanesulfonate Plasma Levels and Risk of Cancer in the General Danish Population. J. Natl. Cancer Inst. 2009.
13. Gart J.J., Krewski D., Lee P.N., Tarone R.E., Wahrendorf J. Statistical Methods in Cancer Research: The Design and Analysis of Long-Term Animal Experiments 1986, vol. 3, no. 79. IARC Scientific Publications/Oxford University Press, New York.
14. Giesy J.P., Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 2001, 35:1339-1342.
15. Hansen K.J., Clemen L.A., Ellefson M.E., Johnson H.O. Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 2001, 35:766-770.
16. ILAR Guide for the Care and Use of Laboratory Animals. National Research Council, Institute of Laboratory Animal Resources 1996, National Academy Press, Washington, DC.
17. Kenny, T.J., 2005. Final report: Perfluorooctanesulfonyl fluoride (POSF; T-7661.4) toxicity study by inhalation administration to CD rats for 13 weeks followed by a 4 week recovery period (Huntingdon Life Sciences LTD, Cambridgeshire, England). Available from United States Environmental Protection Agency Administrative Record 226, Document AR-226-3573.
18. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp P.A. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33:655-780.
19. Lake B.G. Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 2009, 39:582-596.
20. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 2007, 99:366-394.
21. Levene H. Robust tests for equality of variances. Contributions to Probability and Statistics 1960, 278-292. Stanford University Press, Stanford. I. Olkin (Ed.).
22. Martin J.W., Mabury S.A., Solomon K.R., Muir D.C. Bioconcentration and tissue distribution of perfluorinated acids in rainbow trout (Oncorhynchus mykiss). Environ. Toxicol. Chem. 2003, 22:196-204.
23. Martin J.W., Mabury S.A., Solomon K.R., Muir D.C. Dietary accumulation of perfluorinated acids in juvenile rainbow trout (Oncorhynchus mykiss). Environ. Toxicol. Chem. 2003, 22:189-195.
24. McConnell E.E., Solleveld H.A., Swenberg J.A., Boorman G.A. Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J. Natl. Cancer Inst. 1986, 76:283-289.
25. NCI, 2011. National Cancer Institute, Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Bladder. Incidence and Mortality. URL: (accessed 09.06.11). http://seer.cancer.gov/statfacts/html/urinb.html%23incidence-mortality.
26. Olsen G.W., Burris J.M., Mandel J.H., Zobel L.R. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J. Occup. Environ. Med. 1999, 41:799-806.
27. Olsen G.W., Burris J.M., Burlew M.M., Mandel J.H. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 2003, 45:260-270.
28. Olsen G.W., Hansen K.J., Stevenson L.A., Burris J.M., Mandel J.H. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ. Sci. Technol. 2003, 37:888-891.
29. Olsen G.W., Logan P.W., Hansen K.J., Simpson C.A., Burris J.M., Burlew M.M., Vorarath P.P., Venkateswarlu P., Schumpert J.C., Mandel J.H. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring. AIHA J. (Fairfax, Va) 2003, 64:651-659.
30. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115:1298-1305.
31. Peto R., Pike M.C., Day N.E., Gray R.G., Lee P.N., Parish S., Peto J., Richards S., Wahrendorf J. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal 1980.
32. Renner R. Growing concern over perfluorinated chemicals. Environ. Sci. Technol. 2001, 35:154A-160A.
33. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., Butenhoff J.L. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 2003, 183:117-131.
34. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., Butenhoff J.L. Erratum to " sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats" [Toxicology 183 (2003) 117-131]. Toxicology 2003, 192:263-264.
35. Shankar A., Xiao J., Ducatman A. Perfluoroalkyl chemicals and chronic kidney disease in US adults. Am. J. Epidemiol. 2011, 174:893-900.
36. Sohlenius A.K., Eriksson A.M., Hogstrom C., Kimland M., DePierre J.W. Perfluorooctane sulfonic acid is a potent inducer of peroxisomal fatty acid beta-oxidation and other activities known to be affected by peroxisome proliferators in mouse liver. Pharmacol. Toxicol. 1993, 72:90-93.
37. Takacs M.L., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 2007, 95:108-117.
38. Thakur A.K., Berry K.J., Mielke P.W. A FORTRAN program for testing trend and homogeneity in proportions. Comput. Programs Biomed. 1985, 19:229-233.
39. Thomas D.G., Breslow N., Gart J.J. Trend and homogeneity analyses of proportions and life table data. Comput. Biomed. Res. 1977, 10:373-381.
40. Thomford, P.J., 2002. Final report: 104-week dietary chronic toxicity and carcinogenicity with perfluroorctanesulfonic acid postassium salt (PFOS; T-6295) in rats (Covance Laboratory Inc, Madison, WI). Available from United States Environmental Protection Agency Administrative Record 226, Document AR-226-1051a.
41. Umeda Y., Aiso S., Arito H., Nagano K., Matsushima T. Induction of peroxisome proliferation in the liver of biphenyl-fed female mice. J. Occup. Health 2004, 46:486-488.
42. Winer B.J. Analysis of covariance. Statistical Principals in Experimental Design 1971, McGraw-Hill, New York, pp. 752-812. second ed.
43. Wolf C.J., Takacs M.L., Schmid J.E., Lau C., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol. Sci. 2008, 106:162-171.